Engineering enhanced CAR T-cells for improved cancer therapy
- PMID: 34485921
- PMCID: PMC8412433
- DOI: 10.1038/s43018-021-00241-5
Engineering enhanced CAR T-cells for improved cancer therapy
Erratum in
-
Author Correction: Engineering-enhanced CAR T cells for improved cancer therapy.Nat Cancer. 2021 Oct;2(10):1113. doi: 10.1038/s43018-021-00277-7. Nat Cancer. 2021. PMID: 35121886 No abstract available.
Abstract
Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells, the most developed of the CAR T-cell therapies. We discuss the many challenges to CAR-T therapeutic success and innovations in CAR design and T-cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.
Keywords: CAR; T cell; antigen; cancer; chimeric.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8412433/bin/nihms-1719715-f0001.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8412433/bin/nihms-1719715-f0002.gif)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8412433/bin/nihms-1719715-f0003.gif)
![Figure 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8412433/bin/nihms-1719715-f0004.gif)
Similar articles
-
State of the art in CAR T cell therapy for CD19+ B cell malignancies.J Clin Invest. 2020 Apr 1;130(4):1586-1594. doi: 10.1172/JCI129208. J Clin Invest. 2020. PMID: 32235098 Free PMC article. Review.
-
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020. Front Immunol. 2020. PMID: 32849662 Free PMC article. Review.
-
Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.Arch Pharm Res. 2019 Jul;42(7):607-616. doi: 10.1007/s12272-019-01136-x. Epub 2019 Mar 4. Arch Pharm Res. 2019. PMID: 30830661 Review.
-
Advances in modular control of CAR-T therapy with adapter-mediated CARs.Adv Drug Deliv Rev. 2022 Aug;187:114358. doi: 10.1016/j.addr.2022.114358. Epub 2022 May 23. Adv Drug Deliv Rev. 2022. PMID: 35618140 Free PMC article. Review.
-
Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.Ann Hematol. 2020 Aug;99(8):1681-1699. doi: 10.1007/s00277-020-04020-7. Epub 2020 May 9. Ann Hematol. 2020. PMID: 32388608 Review.
Cited by
-
Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.Res Sq [Preprint]. 2024 May 8:rs.3.rs-3243545. doi: 10.21203/rs.3.rs-3243545/v1. Res Sq. 2024. PMID: 38766114 Free PMC article. Preprint.
-
The potential and promise for clinical application of adoptive T cell therapy in cancer.J Transl Med. 2024 May 1;22(1):413. doi: 10.1186/s12967-024-05206-7. J Transl Med. 2024. PMID: 38693513 Free PMC article. Review.
-
PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.J Immunother Cancer. 2024 Apr 8;12(4):e008429. doi: 10.1136/jitc-2023-008429. J Immunother Cancer. 2024. PMID: 38589248 Free PMC article.
-
Harboring CAR-T cells using an injectable scaffold to treat solid tumors.Natl Sci Rev. 2024 Feb 28;11(5):nwae075. doi: 10.1093/nsr/nwae075. eCollection 2024 May. Natl Sci Rev. 2024. PMID: 38577661 Free PMC article. No abstract available.
-
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia.Mol Ther Methods Clin Dev. 2024 Feb 13;32(1):101212. doi: 10.1016/j.omtm.2024.101212. eCollection 2024 Mar 14. Mol Ther Methods Clin Dev. 2024. PMID: 38455264 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials